Non-Hodgkin Lenfomada Tromboz riski ve sıklığının retrospektif analizi
Özet
Valiyev V. Risk and frequency of thrombosis in non-Hodgkin's lymphoma - retrospective analysis of data. Hacettepe University School of Medicine, Thesis in Internal Medicine Department, Ankara, 2019
Introductıon and Purpose: The interrelationships among the malignancies and the development of thrombosis is well known. The occurrence of thrombotic complications in patients with malignancy has important effects such as the need for chronic anticoagulation with the risk of bleeding, possible delays in the administration of chemotherapy and high risk of recurrent thrombosis. The aim of this study was to assess the risk and frequency of thrombosis in Non-Hodgkin's Lymphoma and to demonstrate the incidence of thrombosis incidentally detected, the relationship between sex, age, underlying disease and comorbidities, type of non-Hodgkin's lymphoma, stage of non-Hodgkin's lymphoma disease, type of chemotherapy, ECOG performance were shown.
Material and Methods: The medical data of 220 NHL patients were retrospectively reviewed. Demographic characteristics of the patients were analyzed using Microsoft Office Excel. The general characteristics of the patient group were calculated separately. All analyzes were performed in SPSS 20.0 package program and p value of 0.05 was used as criterion. The frequency and percentage calculations of venous and arterial thrombosis incidence of thrombosis events detected by individuals and random radiological imaging were performed. After the frequency and percentage calculations, thrombosis event, sex, age, additional disease, type of diagnosis, stage, chemotherapy, ECOG variables were used. It was carried out from the independence (chi-square) tests on the data of individuals. Yates' chi-square values were examined in all sex, age, type of diagnosis, stage, ECOG variables.
Findings: Of the 220 NHL patients, 31 (% 14) had thrombosis. The most common thrombosis event was DVT in 8 subjects, and the second common thrombosis event was PTE in 6 patients. PTE and DVT were detected in 2 patients simultaneously. In 15 (% 6.8) of the patients, arterial; Venous thrombosis was found in 17 (% 7.7). İncidental thrombosis was observed in 15 patients (% 6.8) and the most detected event was portal vein thrombosis and splenic infarction, which was determined to be 3 in each of the patients. Thrombosis was found to be statically independent from one of the NHL diagnosis type (p = 1.000; p> 0.05). Thrombosis was detected in 11 of 77 subjects with DBBHL and in 20 of 143 NHL subjects with other subtypes. The ECOG performance (p = 0,000; p <0,05) and advanced disease stage (p = 0,006; p <0,05) showed a significant relationship between thrombosis. Thrombosis was detected in 25 (% 20) of 124 advanced stage individuals. In our study, 20 (% 64.5) patients who had a thrombosis event received Doxorubicin and Cyclophosphamide based chemotherapy protocol.
Results: As a result of the retrospective analysis in our patient cohort, we found that NHL increased the incidence of acquired thrombosis. Advanced ECOG performance and advanced disease stage in NHL patients were shown statistically thrombosis tendency. There were 15 (% 6,8) cases of thrombosis detected by incidental imaging.
Keywords: NHL, DLBCL, Thrombosis, PTE, DVT, ECOG performance